-
1
-
-
84901920026
-
Targeting inflammation in the treatment of type 2 diabetes: time to start
-
COI: 1:CAS:528:DC%2BC2cXosV2lsLw%3D, PID: 24854413
-
Donath MY (2014) Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 13:465–476
-
(2014)
Nat Rev Drug Discov
, vol.13
, pp. 465-476
-
-
Donath, M.Y.1
-
2
-
-
0027459878
-
Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance
-
COI: 1:CAS:528:DyaK3sXnvFaitw%3D%3D, PID: 7678183
-
Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91
-
(1993)
Science
, vol.259
, pp. 87-91
-
-
Hotamisligil, G.S.1
Shargill, N.S.2
Spiegelman, B.M.3
-
3
-
-
0029906375
-
Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM
-
PID: 8666137
-
Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881–885
-
(1996)
Diabetes
, vol.45
, pp. 881-885
-
-
Ofei, F.1
Hurel, S.2
Newkirk, J.3
Sopwith, M.4
Taylor, R.5
-
4
-
-
0034454915
-
No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients
-
COI: 1:CAS:528:DC%2BD3cXisFOqsb0%3D, PID: 10720082
-
Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ (2000) No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 85:1316–1319
-
(2000)
J Clin Endocrinol Metab
, vol.85
, pp. 1316-1319
-
-
Paquot, N.1
Castillo, M.J.2
Lefebvre, P.J.3
Scheen, A.J.4
-
5
-
-
27344441019
-
Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BD2MXhtFWmurnF, PID: 16155368
-
Dominguez H, Storgaard H, Rask-Madsen C et al (2005) Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42:517–525
-
(2005)
J Vasc Res
, vol.42
, pp. 517-525
-
-
Dominguez, H.1
Storgaard, H.2
Rask-Madsen, C.3
-
6
-
-
33646134126
-
Effects of etanercept in patients with the metabolic syndrome
-
COI: 1:CAS:528:DC%2BD28Xkslensrc%3D, PID: 16636217
-
Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK (2006) Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166:902–908
-
(2006)
Arch Intern Med
, vol.166
, pp. 902-908
-
-
Bernstein, L.E.1
Berry, J.2
Kim, S.3
Canavan, B.4
Grinspoon, S.K.5
-
7
-
-
78650917112
-
TNF-α antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome
-
COI: 1:CAS:528:DC%2BC3MXhtFGmsLs%3D, PID: 21047923
-
Stanley TL, Zanni MV, Johnsen S et al (2011) TNF-α antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 96:E146–E150
-
(2011)
J Clin Endocrinol Metab
, vol.96
, pp. E146-E150
-
-
Stanley, T.L.1
Zanni, M.V.2
Johnsen, S.3
-
8
-
-
0036738398
-
Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity in human pancreatic islets
-
COI: 1:CAS:528:DC%2BD38Xnt1ehtbY%3D, PID: 12235117
-
Maedler K, Sergeev P, Ris F et al (2002) Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851–860
-
(2002)
J Clin Invest
, vol.110
, pp. 851-860
-
-
Maedler, K.1
Sergeev, P.2
Ris, F.3
-
9
-
-
34247170807
-
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BD2sXkt1Sjtr4%3D, PID: 17429083
-
Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526
-
(2007)
N Engl J Med
, vol.356
, pp. 1517-1526
-
-
Larsen, C.M.1
Faulenbach, M.2
Vaag, A.3
-
10
-
-
69549105888
-
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
-
COI: 1:CAS:528:DC%2BD1MXht1agtr3P, PID: 19542207
-
Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32:1663–1668
-
(2009)
Diabetes Care
, vol.32
, pp. 1663-1668
-
-
Larsen, C.M.1
Faulenbach, M.2
Vaag, A.3
Ehses, J.A.4
Donath, M.Y.5
Mandrup-Poulsen, T.6
-
11
-
-
53749100698
-
Increased interleukin (IL)-1β messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation
-
PID: 18664535
-
Boni-Schnetzler M, Thorne J, Parnaud G et al (2008) Increased interleukin (IL)-1β messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation. J Clin Endocrinol Metab 93:4065–4074
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. 4065-4074
-
-
Boni-Schnetzler, M.1
Thorne, J.2
Parnaud, G.3
-
12
-
-
84942119421
-
The IL-1 pathway in type 2 diabetes and cardiovascular complications
-
COI: 1:CAS:528:DC%2BC2MXhsFKnsL%2FN, PID: 26412156
-
Herder C, Dalmas E, Boni-Schnetzler M, Donath MY (2015) The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol Metab 26:551–563
-
(2015)
Trends Endocrinol Metab
, vol.26
, pp. 551-563
-
-
Herder, C.1
Dalmas, E.2
Boni-Schnetzler, M.3
Donath, M.Y.4
-
13
-
-
79960086288
-
Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study
-
PID: 21508140
-
van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG, Tack CJ (2011) Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 96:2119–2126
-
(2011)
J Clin Endocrinol Metab
, vol.96
, pp. 2119-2126
-
-
van Asseldonk, E.J.1
Stienstra, R.2
Koenen, T.B.3
Joosten, L.A.4
Netea, M.G.5
Tack, C.J.6
-
14
-
-
84938085085
-
One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus
-
PID: 26073226
-
van Asseldonk EJ, van Poppel PC, Ballak DB, Stienstra R, Netea MG, Tack CJ (2015) One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus. Clin Immunol 160:155–162
-
(2015)
Clin Immunol
, vol.160
, pp. 155-162
-
-
van Asseldonk, E.J.1
van Poppel, P.C.2
Ballak, D.B.3
Stienstra, R.4
Netea, M.G.5
Tack, C.J.6
-
15
-
-
0035979775
-
Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ
-
COI: 1:CAS:528:DC%2BD3MXms1Chtrw%3D, PID: 11533494
-
Yuan M, Konstantopoulos N, Lee J et al (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293:1673–1677
-
(2001)
Science
, vol.293
, pp. 1673-1677
-
-
Yuan, M.1
Konstantopoulos, N.2
Lee, J.3
-
16
-
-
38949119419
-
Salsalate improves glycemia and inflammatory parameters in obese young adults
-
COI: 1:CAS:528:DC%2BD1cXis1ajsr0%3D, PID: 17959861
-
Fleischman A, Shoelson SE, Bernier R, Goldfine AB (2008) Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31:289–294
-
(2008)
Diabetes Care
, vol.31
, pp. 289-294
-
-
Fleischman, A.1
Shoelson, S.E.2
Bernier, R.3
Goldfine, A.B.4
-
17
-
-
64149121817
-
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes
-
COI: 1:CAS:528:DC%2BD1cXpt1Gnsbo%3D, PID: 19337387
-
Goldfine AB, Silver R, Aldhahi W et al (2008) Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 1:36–43
-
(2008)
Clin Transl Sci
, vol.1
, pp. 36-43
-
-
Goldfine, A.B.1
Silver, R.2
Aldhahi, W.3
-
18
-
-
59449090513
-
The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study
-
COI: 1:CAS:528:DC%2BD1MXhtlKisb4%3D, PID: 19104769
-
Koska J, Ortega E, Bunt JC et al (2009) The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 52:385–393
-
(2009)
Diabetologia
, vol.52
, pp. 385-393
-
-
Koska, J.1
Ortega, E.2
Bunt, J.C.3
-
19
-
-
84876485218
-
A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance
-
COI: 1:CAS:528:DC%2BC3sXjslehsrs%3D, PID: 23370525
-
Goldfine AB, Conlin PR, Halperin F et al (2013) A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 56:714–723
-
(2013)
Diabetologia
, vol.56
, pp. 714-723
-
-
Goldfine, A.B.1
Conlin, P.R.2
Halperin, F.3
-
20
-
-
77950885686
-
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial
-
PID: 20231565
-
Goldfine AB, Fonseca V, Jablonski KA et al (2010) The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 152:346–357
-
(2010)
Ann Intern Med
, vol.152
, pp. 346-357
-
-
Goldfine, A.B.1
Fonseca, V.2
Jablonski, K.A.3
-
21
-
-
84879564109
-
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial
-
PID: 23817699
-
Goldfine AB, Fonseca V, Jablonski KA et al (2013) Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med 159:1–12
-
(2013)
Ann Intern Med
, vol.159
, pp. 1-12
-
-
Goldfine, A.B.1
Fonseca, V.2
Jablonski, K.A.3
-
22
-
-
34548431826
-
Increased number of islet-associated macrophages in type 2 diabetes
-
COI: 1:CAS:528:DC%2BD2sXhtV2gs7fE, PID: 17579207
-
Ehses JA, Perren A, Eppler E et al (2007) Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56:2356–2370
-
(2007)
Diabetes
, vol.56
, pp. 2356-2370
-
-
Ehses, J.A.1
Perren, A.2
Eppler, E.3
-
23
-
-
0348230958
-
Obesity is associated with macrophage accumulation in adipose tissue
-
COI: 1:CAS:528:DC%2BD3sXhtVSmtLvO, PID: 14679176
-
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808
-
(2003)
J Clin Invest
, vol.112
, pp. 1796-1808
-
-
Weisberg, S.P.1
McCann, D.2
Desai, M.3
Rosenbaum, M.4
Leibel, R.L.5
Ferrante, A.W.6
-
24
-
-
9144223683
-
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance
-
COI: 1:CAS:528:DC%2BD3sXhtVSmtLvI, PID: 14679177
-
Xu H, Barnes GT, Yang Q et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830
-
(2003)
J Clin Invest
, vol.112
, pp. 1821-1830
-
-
Xu, H.1
Barnes, G.T.2
Yang, Q.3
-
25
-
-
84913543785
-
CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study
-
PID: 24798870
-
Di Prospero NA, Artis E, Andrade-Gordon P et al (2014) CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Diabetes Obes Metab 16:1055–1064
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 1055-1064
-
-
Di Prospero, N.A.1
Artis, E.2
Andrade-Gordon, P.3
-
26
-
-
84959472256
-
CCL2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria
-
580-P (Abstract)
-
Haller HG, Menne J, Eulberg D (2015) CCL2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Diabetes 64(Suppl 1):A148, 580-P (Abstract)
-
(2015)
Diabetes
, vol.64
, pp. A148
-
-
Haller, H.G.1
Menne, J.2
Eulberg, D.3
-
27
-
-
70450189795
-
Inflammation in atherosclerosis: from pathophysiology to practice
-
COI: 1:CAS:528:DC%2BC3cXkvFOhsg%3D%3D, PID: 19942084
-
Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on A (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54:2129–2138
-
(2009)
J Am Coll Cardiol
, vol.54
, pp. 2129-2138
-
-
Libby, P.1
Ridker, P.M.2
Hansson, G.K.3
Leducq Transatlantic Network on, A.4
-
28
-
-
84864545087
-
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
-
COI: 1:CAS:528:DC%2BC38XhtFWmtrfJ, PID: 22850787
-
Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633–652
-
(2012)
Nat Rev Drug Discov
, vol.11
, pp. 633-652
-
-
Dinarello, C.A.1
Simon, A.2
van der Meer, J.W.3
-
29
-
-
32944468985
-
Gout-associated uric acid crystals activate the NALP3 inflammasome
-
COI: 1:CAS:528:DC%2BD28XitFGitLg%3D, PID: 16407889
-
Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241
-
(2006)
Nature
, vol.440
, pp. 237-241
-
-
Martinon, F.1
Petrilli, V.2
Mayor, A.3
Tardivel, A.4
Tschopp, J.5
-
30
-
-
34047174085
-
A pilot study of IL-1 inhibition by anakinra in acute gout
-
PID: 17352828
-
So A, de Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9:R28
-
(2007)
Arthritis Res Ther
, vol.9
, pp. R28
-
-
So, A.1
de Smedt, T.2
Revaz, S.3
Tschopp, J.4
-
31
-
-
84934962576
-
Anakinra treatment in patients with gout and type 2 diabetes
-
PID: 24733251
-
Vitale A, Cantarini L, Rigante D, Bardelli M, Galeazzi M (2015) Anakinra treatment in patients with gout and type 2 diabetes. Clin Rheumatol 34:981–984
-
(2015)
Clin Rheumatol
, vol.34
, pp. 981-984
-
-
Vitale, A.1
Cantarini, L.2
Rigante, D.3
Bardelli, M.4
Galeazzi, M.5
-
32
-
-
84885902717
-
Psoriasis severity and the prevalence of major medical comorbidity: a population-based study
-
PID: 23925466
-
Yeung H, Takeshita J, Mehta NN et al (2013) Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 149:1173–1179
-
(2013)
JAMA Dermatol
, vol.149
, pp. 1173-1179
-
-
Yeung, H.1
Takeshita, J.2
Mehta, N.N.3
-
33
-
-
80053644777
-
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
-
COI: 1:CAS:528:DC%2BC3MXht1OhsLzJ, PID: 21982649
-
Ridker PM, Thuren T, Zalewski A, Libby P (2011) Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162:597–605
-
(2011)
Am Heart J
, vol.162
, pp. 597-605
-
-
Ridker, P.M.1
Thuren, T.2
Zalewski, A.3
Libby, P.4
|